Antitumor response against myeloma cells by immunization with mouse syngenic dendritoma

Hybridoma (Larchmt). 2005 Aug;24(4):182-8. doi: 10.1089/hyb.2005.24.182.

Abstract

In order to generate an immune response against myeloma cells in an homogenous murine model, a stable hybrid cell line (DCSp) was established through the syngenic fusion between mouse dendritic cells (DC) and mouse Sp2/0 myeloma cells. DCSp cells behaved as potent T cell stimulators and were able to induce Sp2/0 specific cytotoxicity. When mice were immunized with irradiated hybrids before SP2/0 injection, they exhibited a significantly higher rate of survival as compared with controls. When tumors were detected, their emergence was not delayed, and time elapsed between tumor clinical perception and death remained unchanged. A humoral immune response was also always associated. We assume that this stable dendritoma cell line can be considered a valuable tool for myeloma studies in an homogenous mouse model. The efficiency of dendritoma as a weapon against tumor cells and the benefit of syngeny in experimental models are discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines / immunology*
  • Cell Division
  • Dendritic Cells / immunology*
  • Hybridomas*
  • Mice
  • Mice, Inbred BALB C
  • Microscopy, Electron
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / pathology
  • T-Lymphocytes, Cytotoxic / cytology

Substances

  • Cancer Vaccines